secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2023-02-13T23:59:59+00:00
Accession:  0001140361-23-006178
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant Q3 net loss widens to $385M; VTAMA revenue $9.2M, RVT-3101 Phase 2b positive
--------------------------------------------------------------------------------

- Net loss of $384.9M ($0.49 per share) for Q3 FY2023, compared to net loss of $306.1M ($0.41) a year ago.
- VTAMA net product revenue $9.2M; nearly 100,000 prescriptions written by ~8,600 prescribers since launch; 57% of commercial lives covered.
- RVT-3101 Phase 2b TUSCANY-2: 31% clinical remission (p=0.01) and 40% endoscopic improvement (p=0.01) at expected Phase 3 dose; biomarker-positive patients achieved 40%/56% rates.
- Completed $230M upsized equity offering; pro forma cash $1.9B, extending runway into 2H 2025.
- Topline data expected from ADORING 1 (VTAMA in atopic dermatitis) in March 2023 and ADORING 2 in May 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123006178/0001140361-23-006178-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123006178/brhc10048029_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-006178

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer